Hair relaxer uterine cancer lawsuit MDL 3060: the 11,500+ pending cases, the 2022 NIH Sister Study that triggered the litigation, the Daubert phase that determines settlement values, and the late 2026 first bellwether trial

If you regularly used chemical hair relaxers or straighteners over a period of years and were subsequently diagnosed with uterine, endometrial, or ovarian cancer (or uterine fibroids requiring hysterectomy), this is the active litigation that may apply to your case. The MDL is In re: Hair Relaxer Marketing Sales Practices and Products Liability Litigation, MDL 3060, consolidated in the U.S. District Court for the Northern District of Illinois before Judge Mary M. Rowland. As of May 1, 2026, the MDL has 11,526 pending cases, making it one of the largest active pharmaceutical/product liability mass torts in the federal system.

The litigation alleges that long-term exposure to endocrine-disrupting chemicals in chemical hair relaxers (phthalates, parabens, formaldehyde-releasing agents, and similar substances) substantially increases the risk of uterine, endometrial, and ovarian cancers. The science is well-established by epidemiological studies but the case-by-case causation analysis is contested; the Daubert proceedings currently underway will substantially shape the bellwether trials and the eventual settlement framework.

The science that triggered the litigation

The litigation traces its origin to a single substantial study: the October 2022 NIH Sister Study published in the Journal of the National Cancer Institute. The Sister Study followed approximately 33,497 women aged 35-74 over an average of 10.9 years and tracked their hair product use against cancer outcomes.

The study found that women who used chemical hair straighteners more than four times per year had more than twice the risk of developing uterine cancer compared to women who never used these products (Hazard Ratio approximately 2.55). The association was strongest for Black women, who are also disproportionately likely to be regular hair relaxer users (60-80% of Black women report using these products at some point, with substantial regular use beginning in childhood and continuing into adulthood).

Subsequent studies have refined and expanded the findings. The biological mechanism is plausible: many hair relaxer products contain chemicals that are documented endocrine disruptors (substances that interfere with the body's hormone system). Endocrine disruption affects uterine and reproductive tissues, which are hormone-responsive. The combination of high-frequency exposure (many women use these products every 4-8 weeks for decades), high-temperature application (which increases chemical absorption through the scalp), and prolonged contact time (relaxer products are typically left on the scalp for 15-30 minutes per application) produces substantial cumulative exposure to the relevant chemicals.

The defendants contest the strength of the causal link, the applicability of the study findings to individual plaintiffs, and the adequacy of the warning label information available before 2022. The Daubert proceedings will address whether the plaintiffs' causation experts can testify at trial; the defendants are filing motions to exclude expert testimony, and the rulings will substantially shape what the bellwether juries hear.

The MDL structure

MDL 3060 was created in February 2023 by the Judicial Panel on Multidistrict Litigation. Judge Mary M. Rowland of the Northern District of Illinois was assigned to preside. Magistrate Judge Beth W. Jantz handles discovery matters.

The defendants include the substantial range of hair relaxer manufacturers:

L'Oréal USA, Inc. (and L'Oréal S.A., its French parent — the parent has been the subject of a Hague Convention motion for international judicial assistance to obtain documents).

Revlon, Inc.

Wella International Operations Switzerland Sàrl.

SoftSheen-Carson LLC.

Strength of Nature Global LLC.

John Paul Mitchell Systems.

Avlon Industries.

Bronner Brothers (Judge Rowland rejected an attempt by Bronner Brothers to dismiss many cases against it).

Namaste Laboratories LLC.

House of Cheatham.

Dermoviva.

Dudley Beauty Corp.

Advanced Beauty Systems.

Several other manufacturers and distributors.

The major brands at issue include Dark and Lovely, Just for Me, Optimum Care, Olive Oil, Soft & Beautiful, ORS, and others. The MDL has consolidated cases from across the federal system, and the substantial majority of pending cases have been removed from state court to the MDL framework.

The bellwether process

The bellwether trial process is the framework through which the MDL identifies representative cases to try first, with the verdicts informing settlement negotiations for the remaining cases. The substantial process has been ongoing throughout 2024-2026:

By April 30, 2025, plaintiffs and defendants each submitted lists of 20 representative cases they considered strongest for their respective sides (40 total nominations).

The court narrowed the pool to 32 cases for further discovery.

Ultimately, 10 cases were selected for early bellwether trials.

Only cases involving diagnoses of uterine, endometrial, or ovarian cancer are eligible for the bellwether pool. Uterine fibroid cases (without cancer diagnosis) may be litigated but are not in the bellwether selection.

Bellwether discovery is currently underway. Each bellwether plaintiff has been deposed, and the manufacturer document production is proceeding under the MDL discovery plan. Daubert motions are being briefed on key causation experts; the outcomes of these motions will substantially shape the bellwether trials.

The first bellwether trial is scheduled for late 2026 according to court schedules current as of May 2026. The second bellwether trial is scheduled approximately three months after the first. The plaintiffs' bar pushed for trials starting in September 2025; the defendants pushed for 2026; the court adopted a middle ground that has produced the late 2026 schedule.

What qualifying cases look like

For an individual case to be filed within MDL 3060 and to fit the bellwether profile:

Diagnosis. Uterine cancer, endometrial cancer, ovarian cancer, or (in some categories) uterine fibroids requiring hysterectomy. The diagnosis must be confirmed by pathology; clinical suspicion alone is not sufficient. Cancer staging and treatment history are relevant for damages valuation but not for eligibility.

Hair relaxer use. Regular use of chemical hair relaxers for an extended period, typically a year or more, with the substantial majority of strong cases involving 5+ years of regular use. The plaintiff must be able to identify the brand(s) of relaxer used; cases without brand identification are substantially weaker because they cannot connect the injury to a specific defendant.

Causation timing. The cancer diagnosis must postdate the relaxer use. Defendants raise causation challenges where the diagnosis is very close to the period of use; the more robust cases have multi-year latency periods between exposure and diagnosis, consistent with cancer biology.

Documentation. Medical records, pathology reports, hair relaxer product receipts (or photos of packaging), oncology treatment records, and any other documentation supporting the use pattern and the cancer diagnosis. The plaintiff fact sheet (PFS) process in MDL 3060 requires substantial documentation; incomplete PFSs have been the subject of multiple court rulings.

The Daubert phase

The current Daubert phase is the substantial procedural fulcrum. Daubert motions ask the court to exclude expert testimony as unreliable or insufficiently grounded in accepted scientific methodology. The plaintiffs' causation experts are the primary target; if their testimony is excluded or substantially limited, the plaintiffs' case is materially weakened.

The defendants are arguing:

The 2022 NIH Sister Study, while large, is observational rather than experimental, and cannot establish causation at the individual case level.

The specific chemicals identified as causal factors are present in many products beyond hair relaxers; cases cannot reliably attribute the cancer to relaxer exposure rather than to other endocrine-disrupting chemical exposures.

The biological mechanism, while plausible, has not been demonstrated through experimental studies with the specificity needed for individual case causation.

The plaintiffs are arguing:

The epidemiological evidence is sufficient under Daubert and Federal Rule of Evidence 702 to support expert testimony on causation.

Multiple independent studies support the link, providing replication that strengthens the causal inference.

Internal manufacturer documents (under discovery) demonstrate that defendants were aware of the potential health risks but failed to adequately warn consumers.

The outcomes of these motions will be substantially case-shaping. If the plaintiffs' causation experts survive Daubert challenges, the cases proceed to trial with strong scientific support. If the experts are excluded or substantially limited, the cases face a much harder path.

Settlement framework expectations

There is no global settlement as of May 2026. Settlement discussions typically intensify after the first bellwether trial produces a verdict, because the verdict provides a benchmark for valuing the remaining cases.

Plaintiffs' counsel expectations vary widely:

For strong cases (clear diagnosis, long history of regular use, brand identification, no confounding factors), settlement values in the range of $100,000 to $1,500,000 per case are commonly discussed, with substantial variation based on injury severity and individual case factors.

For weaker cases (shorter use history, multiple confounding chemicals, less clear brand identification), settlement values are substantially lower.

The substantial number of pending cases (11,500+) makes individual case-by-case settlement unrealistic. The likely settlement framework is a structured settlement program with claim categorization and tier-based payments, similar to the framework used in the valsartan NDMA litigation and other large pharmaceutical mass torts.

The defendants' motivation to settle is substantial. Continued litigation costs are substantial, and the bellwether verdicts may produce results that establish broad liability across the manufacturer defendants. Most pharmaceutical/product liability mass torts settle after the first few bellwether verdicts; few proceed to trial in the substantial majority of cases.

The state-court parallel

A small portion of hair relaxer cases remain in state court rather than the MDL. Some plaintiffs have specific procedural reasons to keep their cases in state court (different evidentiary rules, more favorable jury pools, or specific procedural advantages). State courts have largely cooperated with the MDL by staying proceedings or coordinating discovery, but the MDL is the substantial center of gravity for the litigation.

A proposed consumer class action seeking economic damages (refunds for product purchases, medical monitoring funds for asymptomatic regular users) continues to proceed alongside the personal injury cases. The class action framework is structurally different from the MDL; class members would not need to demonstrate individual cancer diagnoses but would need to demonstrate purchase and use of the products.

What documentation matters for individual cases

For someone considering filing or who has filed a hair relaxer case:

Medical records establishing the cancer diagnosis. Pathology reports are essential; clinical history alone is not sufficient. The specific cancer type (uterine, endometrial, ovarian) and stage are documented in oncology records.

Hair relaxer use history. Receipts, packaging photos, salon records, or other documentation establishing the brand(s) used and the frequency of use over the relevant period. For users without contemporaneous documentation, sworn declarations describing the use pattern can support the claim but are weaker than contemporary documentation.

Salon records (if applicable). Many regular hair relaxer users had professional applications. Salon records (if obtainable) provide the strongest documentation of brand and frequency.

Symptom timeline. Documentation of when symptoms began and how they relate to the use history. Multi-year latency between exposure and symptom emergence is the typical pattern.

Treatment history. Oncology treatment records (surgery, chemotherapy, radiation, hormonal therapy) document the severity of the injury and inform the damages calculation.

How hair relaxer cases compare to other mass torts

The framework shares features with several Halstonberg-covered mass torts:

Elmiron pigmentary maculopathy involves substantial long-term exposure to a chemical product (medication in that case, hair relaxer here) with delayed onset of injury and substantial post-market data accumulation.

Risperdal gynecomastia involves a pharmaceutical product with substantial endocrine effects; the failure-to-warn framework is similar.

Cartiva SCI implant involves a medical device with substantial post-market failure rate disclosure; the MDL is at a similar procedural stage.

Valsartan NDMA contamination involves chemical exposure through medication; the MDL settlement framework for valsartan has produced multiple confidential settlements that may inform the hair relaxer framework.

The hair relaxer MDL is distinctive in the substantial size of the affected population (millions of regular hair relaxer users in the United States), the disproportionate impact on Black women (which has substantial regulatory and policy implications beyond the litigation), and the strength of the epidemiological evidence supporting the causal link.

Practical guidance

For someone who used hair relaxers and was subsequently diagnosed with uterine, endometrial, or ovarian cancer:

The MDL is actively accepting new cases. Filing now positions the case within the substantial framework that will shape the settlement values; cases filed after settlement negotiations begin may be less favorably positioned.

The plaintiff fact sheet (PFS) process is substantial. Working with counsel familiar with the MDL framework ensures complete and accurate documentation, which is critical to case valuation.

Document your use history while memory is fresh. Photos of products, receipts, salon records, and sworn declarations from family members who witnessed the use can support the case if contemporaneous documentation is unavailable.

Engage oncology treatment records to support the diagnosis. The pathology reports are the foundation; treatment history supports the damages calculation.

Be cautious about settlement offers from advertised "claims companies" that are not actual law firms. The hair relaxer space has substantial advertising activity; substantial portions of that advertising lead to fee-sharing arrangements that may not be in your interest. Counsel actively practicing in MDL 3060 is the correct contact.

For someone who used hair relaxers but has not been diagnosed with the qualifying cancers, the medical monitoring framework may apply if the proposed class action is certified. The medical monitoring claim seeks to establish a fund for ongoing screening, not for individual injury compensation.

For someone whose family member was diagnosed and has died, wrongful death and survival cases are part of the MDL framework. The case is brought by the estate or surviving family members; the substantial process is similar but with additional procedural elements.

The litigation is in the highest-leverage phase. The next 12-18 months will substantially define the settlement framework. Cases filed and worked up during this phase typically receive substantial benefit from the structural posture of the MDL; later-filed cases may be processed through a more compressed framework with less individualized attention.